Our clinical development program is focused on improving the clinical benefit of late-stage cancer patients utilizing innovative epigenetic approaches targeting histone deacetylases (HDACs) and lysine-specific demethylase 1 (LSD1) either in monotherapy, or in combination with existing therapies.
Our most advanced program evaluating resminostat in patients with cutaneous T‑cell lymphoma (CTCL), is at the pivotal stage of development in more than 50 centers in 11 European countries.
Addition of resminostat to the standard of care sorafenib resulted in prolonged time until disease progression and a substantial benefit in median overall survival in a large subgroup of patients with a normal to high platelet count at study entry (50% of all patients in the study).
At median, patients in this subgroup treated with resminostat and sorafenib survived for 13.7 months compared to 5.1 months in patients treated with sorafenib alone.
The Phase II trial evaluated the combination of sorafenib and resminostat versus sorafenib as first-line therapy in 170 patients with liver cancer (hepatocellular carcinoma, HCC) in Japan and Korea.